Recent Quotes

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate isJeuveau, an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
EOLS	Evolus	12.77	0.18	1.43%		691.1M

Evolus Frequently Asked Questions

How do I buy Evolus (EOLS) stock?

You can purchase shares of Evolus (NASDAQ: EOLS) through any online brokerage.

View our list of the best stock brokerages.

Who are Evolus's (EOLS) competitors?

Other companies in Evolus’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), Verona Pharma (NASDAQ:VRNA), Tarsus Pharmaceuticals (NASDAQ:TARS), ANI Pharmaceuticals (NASDAQ:ANIP) and Provention Bio (NASDAQ:PRVB).

What is the target price for Evolus (EOLS) stock?

The latest price target for Evolus (NASDAQ: EOLS) was reported by Barclays on May 13, 2021. The analyst firm set a price target for 7.00 expecting EOLS to fall to within 12 months (a possible -45.18% downside). 10 analyst firms have reported ratings in the last year.

Current Stock Price for Evolus (EOLS)?

The stock price for Evolus (NASDAQ: EOLS) is $12.77 last updated Fri Jun 18 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Does Evolus (EOLS) pay a dividend?

There are no upcoming dividends for Evolus.

When is Evolus (NASDAQ:EOLS) reporting earnings?

Evolus does not have any upcoming earnings scheduled.

Is Evolus (EOLS) going to split?

There is no upcoming split for Evolus.

What sector and industry does Evolus (EOLS) operate in?

Evolus is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.